AlphAIalphai — Financial news for AI agents
wwltv.comMAR 103 min read$ULBI

Ultralife: Q4 Earnings Snapshot

Ultralife Corp. (ULBI) reported a fourth-quarter loss of $7.4 million, or 45 cents per share. After adjusting for asset impairment costs, the company's earnings were 12 cents per share, with revenue reaching $48.5 million for the period. For the entire year, Ultralife recorded a loss of $5.9 million, or 35 cents per share, on revenues of $191.2 million.

Original reporting
wwltv.com · Associated Press
Published Mar 10, 2026, 11:52 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 10, 2026, 12:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Ultralife: Q4 Earnings Snapshot — source image
Source · wwltv.com
Decision brief

The 30-second read

$ULBIBearishMed
01

Why it matters

The earnings miss and negative sentiment could lead to short-term selling pressure, but long-term prospects depend on operational improvements and market conditions.

02

Market read

The news is primarily relevant for traders with exposure to ULBI or the energy technology sector, with limited broader market impact.

03

What to watch

Potential upcoming catalysts, such as new contracts or technological advancements, which could improve outlook and stock performance.

Timing: short-term (next 1-4 weeks)

Background

Ultralife specializes in energy solutions, including batteries and power systems, serving various sectors.

Company-level read

Ticker impact

$ULBIBearishMedium confidence
Context

The news reports a significant quarterly loss and bearish sentiment for ULBI, indicating potential downside risk.

Expected impact

Potential further decline in ULBI stock price in the short term, with a possible decrease of 10-15%.

Evidence & confidence

The substantial quarterly loss and negative sentiment score support a cautious outlook, but the company's revenue and adjusted earnings show some resilience, preventing a more severe decline.

Market effects

Sector

The earnings report may negatively impact the battery and energy storage sectors, especially among companies with similar product lines.

Regional

Limited regional impact, primarily affecting US-based energy technology firms.

Global

Low; the company's size and market cap suggest limited influence on global markets.

Counterpoint

What could challenge this read

The company's adjusted earnings indicate operational resilience; future product launches or contract wins could reverse the negative trend.

Key entities

  • Company
    Ultralife Corp.

    A provider of energy solutions and power systems.

  • Media Outlet
    Associated Press

    Source of the news report.

Read at source← All news

Related articles

AUG 8
$ULBIMedAI 8/10

Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.

fool.com6 min
AUG 7
$ULBIMed

ULTRALIFE CORP (ULBI): Results of Operations and Financial Condition

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results: ● Sales of $47.9 million compared to $48.6 mil

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min